IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are the most common inert non
Hodgkin's lymphoma (iNHL). The standard first-line treatment of advanced FL / MZL is based on
rituximab. Whether combined with chemotherapy or not, iNHL can induce lasting remission, but
most of it is usually incurable. Therefore, early treatment of advanced iNHL should focus on
protecting the bone marrow function of patients. Although the first-line immunochemotherapy
offer high efficacy but also high incidence of toxicity. Phosphatidylinositol 3-kinase (PI3K)
pathway plays an important role in the occurrence and development of B-cell malignant tumors.
Studies have shown that PI3K inhibitor alone has good antitumor effect and tolerance in
patients with recurrent refractory iNHL. In addition, PI3K inhibitor combined with rituximab
showed better prognosis compared with rituximab monotherapy in FL / MZL patients. Therefore,
the chemo-free regime, PI3K inhibitor in combination with rituximab may explore a new avenue
for FL and MZL patients.